News >

Frontline Maintenance Niraparib Improves PFS in Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Monday, Jul 15, 2019

Hal Barron, MD

Hal Barron, MD

Niraparib (Zejula) as a maintenance treatment demonstrated a statistically significant improvement in progression-free survival (PFS) compared with placebo in patients with ovarian cancer following first-line platinum-based chemotherapy, regardless of biomarker status, meeting the primary endpoint of the phase III PRIMA (ENGOT-OV26/GOG-3012) trial.1

Under the Prescription Drug User Fee Act, the FDA must make a decision on the application by October 24, 2019.


  1. GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting. GlaxoSmithKline. Published July 15, 2019. Accessed July 15, 2019.
  2. U.S. Food and Drug Administration accepts GSK’s application for ZEJULA (niraparib) in late stage ovarian cancer with priority review. GlaxoSmithKline. Published June 24, 2019. Accessed June 24, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication